Perrigo Company

At the Canaccord growth conference Perrigo presented a 3‑S plan (stabilize, simplify, strengthen) to accelerate its turnaround, including portfolio simplification and a focus on category-led innovation. Management expects annual savings of €80–100 million, about 80% of which are planned for 2026, and a rebound in demand in the second half of 2026. E‑commerce is growing significantly faster than brick-and-mortar retail and should drive market share gains; strategic reviews cover infant nutrition and oral care, and disposals to reduce debt are possible. Perrigo stresses that implementing the measures and improving trade relationships with partners such as Walmart, Dollar General and Amazon should lay the foundation for long-term growth. » Más en de.investing.com

Perrigo reported adjusted diluted EPS of $0.50 for Q2 2026 (consensus $0.34) and adjusted core EPS of $0.46 on revenue of about $1.02 billion, sending the stock up roughly 24%. The unexpectedly strong result was attributed to aggressive cost cuts and operational discipline under the “Three‑S” strategy, although core net sales declined about 3.1%. The sale of the dermocosmetics unit generated approximately €305.6 million and will be used to reduce debt; management reiterated full‑year guidance of adjusted total EPS of $2.00–$2.30 and adjusted core EPS of $2.25–$2.55. » Más en de.investing.com

Perrigo's board of directors has approved a quarterly dividend of $0.29 per share, payable on September 15, 2026 to shareholders of record on August 28, 2026. On an annual basis this corresponds to $1.16 per share. Perrigo markets over-the-counter self-medication products primarily in North America and Europe. » Más en de.investing.com